Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Table: Stop the Madness: How IMC-C225 Halts the Spread of Cancer


1) Cells normally divide to produce more cells only as the body needs them. This process is controlled in part by "oncogenes"--genes that direct cell growth--and by tumor-suppressor genes, which are in charge of cell death. Some cancers occur when a defective oncogene, operating in the nucleus of a cell, sends out a flood of protein signals that cause the cell to embark on a course of rapid cell division. The resulting tumor cells proliferate--urged on by growth signals in the blood stream that attach to the surface of the cells. The tumor-suppressor genes that would normally stop this proliferation either can't keep up or break down.

2) One of the most important cellular signals produced by the oncogene is called epidermal growth factor (EGF). Normally in short supply, it is found in excess amounts in up to half of all types of malignant tumors. While the surface of a normal cell may have about 10,000 EGF receptors, cancer cells can have a million or more. EGF binds to its receptors on the surface of a cell and then triggers a cascade of enzymes inside that play an important role in keeping the tumor alive, well-nourished, and spreading.

3) IMC-C225 is an antibody developed in the lab that identifies and locks onto the receptors of a cancer cell before EGF can reach it, in essence gumming up the trigger. The result: Growth enzymes are not activated, and the cell eventually stops dividing.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus